{"id":18338,"date":"2020-06-30T14:09:37","date_gmt":"2020-06-30T14:09:37","guid":{"rendered":"https:\/\/dejalex.com\/it\/?p=18338"},"modified":"2020-07-02T14:15:19","modified_gmt":"2020-07-02T14:15:19","slug":"italian-court-of-appeal-awards-eur-15-mio-damages-in-pharma-patent-case-for-40-days-infringement","status":"publish","type":"post","link":"https:\/\/www.dejalex.com\/it\/2020\/06\/italian-court-of-appeal-awards-eur-15-mio-damages-in-pharma-patent-case-for-40-days-infringement\/","title":{"rendered":"ITALIAN COURT OF APPEAL AWARDS EUR 1,5 MIO DAMAGES IN PHARMA PATENT CASE FOR 40 DAYS INFRINGEMENT"},"content":{"rendered":"<p>Whilst the Italian Courts are not famous for awarding substantial damages in IP cases, a recent decision of the Rome Court of Appeal seems to have gone in the opposite direction, albeit taking a very long time to deliver the result. In this article, we report on a case started in 2012, which came to its conclusion in 2020 with a second instance judgment that awarded the holder of a significant pharmaceutical patent, EUR 1.5 mio damages approximately to compensate an infringement that lasted 40 days&#8230;<\/p>\n<p><a href=\"http:\/\/patentblog.kluweriplaw.com\/2020\/06\/30\/italian-court-of-appeal-awards-eur-15-mio-damages-in-pharma-patent-case-for-40-days-infringement\/?doing_wp_cron=1593699096.3250770568847656250000\" rel=\"noopener\" target=\"_blank\">Kluwer Patent Blog<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2114 aligncenter\" src=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2020\/07\/20200630_Kluwer-Patent-Blog_Italian-Court-of-Appeal-awards-EUR-15-mio-damages-in-pharma-patent-case-for-40-days-infringement.jpg\" alt=\"\" width=\"557\" height=\"789\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2020\/07\/20200630_Kluwer-Patent-Blog_Italian-Court-of-Appeal-awards-EUR-15-mio-damages-in-pharma-patent-case-for-40-days-infringement.pdf\" target=\"_blank\" rel=\"noopener\"><i  class=\"x-icon x-icon-download\" data-x-icon-s=\"&#xf019;\" aria-hidden=\"true\"><\/i> Scarica l&#8217;articolo<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[x_icon type=\"tag\"] Propriet\u00e0 Intellettuale, Farmaceutico e Life Sciences<\/p>\n","protected":false},"author":3,"featured_media":220,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[370,341,422,307],"tags":[],"class_list":["post-18338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmaceutico-e-life-sciences","category-proprieta-intellettuale","category-pubblicazioni","category-roberto-jacchia-it"],"_links":{"self":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/18338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/comments?post=18338"}],"version-history":[{"count":1,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/18338\/revisions"}],"predecessor-version":[{"id":18345,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/18338\/revisions\/18345"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media\/220"}],"wp:attachment":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media?parent=18338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/categories?post=18338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/tags?post=18338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}